Results 111 to 120 of about 577,051 (308)
Advanced Healthcare Materials, EarlyView.The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan +13 more
wiley +1 more source
Perceived Social Support among Chinese American Hemodialysis Patients [PDF]
, 2005 Social support is linked to improved health outcomes both in Western and Asian societies and is a vital factor in a patient\u27s adjustment to end-stage renal disease and its treatment regimen.
Wong, Kaklam
core +1 more source
End-stage renal disease in China
Kidney International, 1996 A 33-year-old man with chronic renal failure due to glomerulonephritis was referred to the Jinling Hospital because of severe anemia, anorexia, nausea, and weakness during the preceding 2 months. Ten years ago, he was diagnosed as having chronic nephritis with proteinuria, hematuria, and edema.
openaire +2 more sources
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Advanced Healthcare Materials, EarlyView.Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
Cancer screening in end-stage renal disease
Saudi Journal of Kidney Diseases and Transplantation, 2009 The increased risk of cancer after renal transplantation is well documented; however there is less agreement about the prevalence and risk of cancer in patients on dialysis. Although, certain cancers such as those of the kidney and urinary tract are more
Rao Shobhana
doaj
Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option? [PDF]
, 2017 Complement factor H (CFH) mutation is one of the causes of atypical haemolytic uraemic syndrome (aHUS). Patients with CFH mutation-associated aHUS progress often to end-stage renal disease despite plasma exchange therapy.
Dickenmann, Michael +6 more
core
Advanced Healthcare Materials, EarlyView.Recent studies reported immunosuppressive properties of specific MXene nanomaterials. Their intravenous injection into the bloodstream of laboratory animals has been a common delivery method to suppress systemic inflammation and prevent transplant rejection.
Alireza Rafieerad +2 more
wiley +1 more source
Re: Risk of End-Stage Renal Disease Following Live Kidney Donation
Journal of Urological Surgery, 2014 The authors compare the risk of end-stage renal disease (ESRD) in 96217 kidney donors in the United States, followed for a median of 7.6 years with that of a healthy cohort of 20024 nondonors, followed for a median of 15 years of who are at equally low ...
Muzaale AD +6 more
doaj
Advanced Materials, EarlyView.A nano‐interception strategy disrupts pathogenic fibroblast–macrophage crosstalk in chronic heart failure. Scalable Prussian blue nanoparticles selectively sequester CCL2 via ultrahigh‐affinity binding, preventing CCR2+ macrophage recruitment and breaking a key fibro‐inflammatory circuit. This approach demonstrates robust efficacy in murine and porcine
Bo Chen +16 more
wiley +1 more source
Advanced Materials, EarlyView.Controlling the protein corona formation onto carbon nanomaterials (CNMs) enhances their functionalities as platforms for cancer theranostics. Here, we reviewed the effects of the intrinsic and acquired properties of CNMs on protein corona formation, the consequent biological and toxicological outcomes, and the strategies to reshape corona formation ...
Yajuan Zou +5 more
wiley +1 more source